Study of SYS6010 plus osimertinib for advanced EGFR-mutant NSCLC
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new drug called SYS6010 combined with osimertinib for people with advanced non-small cell lung cancer that has specific EGFR mutations. It aims to see if this combination works better than current treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 75 years old.
- You have advanced non-small cell lung cancer (stage IIIB/IIIC or IV) with an EGFR mutation (like exon 19 deletion or L858R).
- You have not had prior targeted therapy (EGFR-TKIs) or other systemic treatments for advanced disease, unless you had adjuvant therapy and it progressed more than 6 months after finishing.
- You have at least one tumor that can be measured on scans (CT or MRI).
- You are in good general health (ECOG score 0 or 1) and expected to live at least 3 months.
- Blood tests show your major organs (like liver, kidneys, and blood cells) are working well enough.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 trial studies TY-9591 in people with locally advanced or metastatic non-small cell lung cancer (NSCLC) that has specific EGFR gene changes. It’s for those who haven’t had earlier medicines for advanced lung cancer, and it aims to see if the drug works better or safer than the comparison treatment.
This trial tests whether adding SYS6010 to osimertinib before surgery works better than osimertinib alone for people with a type of lung cancer that has an EGFR mutation. The goal is to shrink the tumor and improve surgery outcomes.
This trial tests a new drug called SYS6010 compared to standard chemotherapy for people with EGFR-mutated lung cancer that has stopped responding to pill treatments. It may offer a new option if your current EGFR TKI is no longer working.
This trial studies osimertinib in people with advanced or metastatic lung cancer that has specific EGFR gene changes. It aims to see how well this targeted medicine can control the cancer when surgery or radiotherapy won’t work.
This trial tests a new study drug called NXP900 combined with the targeted therapy osimertinib for people with advanced EGFR-mutated lung cancer who have already been treated with osimertinib. The goal is to see if the combination can help shrink tumors or slow cancer growth.
This study tests adding chemotherapy (pemetrexed and carboplatin) to the targeted drug osimertinib (Tagrisso) for people with a specific type of advanced lung cancer (EGFR-mutated adenocarcinoma) that is not controlled well by osimertinib alone. The goal is to see if the combination helps people live longer or better.
Hear when a new NSCLC trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.